WP Intelligence Briefing | Washington’s new push on drug pricing

Описание: President Donald Trump’s administration and Congress are both accelerating efforts to rein in prescription drug costs as the midterm elections approach. Medicare price negotiations are underway. Lawmakers have passed legislation targeting pharmacy benefit managers. And the Centers for Medicare and Medicaid Services (CMS) is testing new payment models that would allow state Medicaid to be reimbursed if new expensive therapies don’t work for patients. At the same time, pharmaceutical companies have raised launch prices — an area the federal government does not directly regulate — intensifying debate over how the system should function.

WPI Lead Health Care Analyst Rebecca Adams, CEO of Patients for Affordable Drugs Merith Basey and executive VP of policy and research for the Pharmaceutical Research and Manufacturers of America (PhRMA) Elizabeth Carpenter examined Medicare price negotiations, PBM reform, rising launch prices, and the implications for innovation, patient affordability, and the broader health care system.

The briefing was held on February 20 and moderated by Luiza Savage, editorial director of WP Intelligence.

• Medicare Advantage shows the limits of cost control (https://wpintelligence.washingtonpost...) by Rebecca Adams
• Washington tests a new way to bargain over high-cost cures (https://wpintelligence.washingtonpost...) by Rebecca Adams
• Washington intensifies efforts to curb drug prices (https://wpintelligence.washingtonpost...) by Rebecca Adams